[{"name":"In TPS\u003E50%, what is best in 1st-line: single agent Pembrolizumab or CT-IO combination?","mode":"","is_cme":false,"info":{"presentation":"In TPS>50%, what is best in 1st-line: single agent Pembrolizumab or CT-IO combination?","session":"Session 3","presenter":"S. Peters","photo":null},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/lung2019\/6\/v\/3_1c.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/lung2019\/6\/v\/3_1c.mp4","cover":"","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/lung2019\/6\/v\/3_1c.vtt"}]}]{"provider":"CTI","provider_live":0,"type":1,"code":"8L240402VK"}